This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

Volume: 35, Issue: 1
Published: Nov 20, 2021
Abstract
IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single-center retrospective cohort study enrolling moderate-to-severe psoriasis patients from September...
Paper Details
Title
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
Published Date
Nov 20, 2021
Volume
35
Issue
1
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.